Activist investors have moved in on Bristol-Myers Squibb, including Carl Icahn, who has a long history of pushing drugmakers to put themselves on the block.

This year’s flu vaccine is working for almost half of recipients, the CDC says in an update on what it’s calling a “moderate” season.

J&J is the most admired pharma company, according to Fortune's annual corporate poll, for the fourth year in a row and comes in at No. 13 among all…

​​​​​​​Gilead might not enjoy suffering its recent, severe hep C revenue downfall, but according to one analyst, the rest of biopharma stands to benefit from…

AbbVie’s former blockbuster AndroGel faces a class-action lawsuit over side effects—and a trial of a different sort as new testosterone-replacement data paint…

Ahead of the Supreme Court’s hearing in Amgen v. Sandoz “patent dance” case, biosimilars advocates are criticizing a lower court's 'detrimental…

Celgene’s late-stage pill, ozanimod, could hit $2b in sales and add pressure to an already competitive oral MS market, analysts say.

Eli Lilly, Pfizer, Takeda, Bristol-Myers Squibb and Gilead are set to hit the patent cliff this year with some of their respective big-sellers.

AstraZeneca snagged $250 million-plus for its cancer drug Zoladex in the U.S., where it brought in only $69 million last year. The deal, AZ's latest slim-…

Pharma